The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab.
 
Stefano Cascinu
Consulting or Advisory Role - Merck Serono; Roche/Genentech
Research Funding - Amgen (Inst); Merck (Inst)
 
Gerardo Rosati
No Relationships to Disclose
 
Guglielmo Nasti
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Bayer
Speakers' Bureau - Roche
Research Funding - Sanofi
 
Alberto Zaniboni
Consulting or Advisory Role - Sanofi
 
Paolo Marchetti
Honoraria - Amgen; Roche Canada
 
Massimo Aglietta
No Relationships to Disclose
 
Domenico Bilancia
No Relationships to Disclose
 
Rosario Vincenz Iaffaioli
No Relationships to Disclose
 
Vittorina Zagonel
No Relationships to Disclose
 
Monica Giordano
No Relationships to Disclose
 
Domenico C. Corsi
No Relationships to Disclose
 
Francesco Ferraú
No Relationships to Disclose
 
Roberto Labianca
Honoraria - Lilly; Roche/Genentech
Consulting or Advisory Role - Lilly; Sanofi
 
Monica Ronzoni
No Relationships to Disclose
 
Irene Claudia Floriani
No Relationships to Disclose